All Type of News
Drugmakers to be under pressure to lower drug costs
Domestic and foreign pharmaceutical firms will be obliged to reduce prices of insurance-covered drugs as the Health Insurance Review and Assessment Service is set to evaluate the economic effectiveness of 3,000 medici...
Korean antihypertensive drugs increase market share
Korean-made antihypertensive drugmakers have taken up bigger share in the final quarter of last year, an industry report showed recently.
According to UBIST data, Chong Kun Dang Pharmaceutical’s Salotan (losartan) ...
3,111 items to be re-evaluated in 2009
The Korea Food and Drug Administration announced that a total of 3,111 drugs will be re-evaluated this year under the provisions of the Korea Pharmaceutical Affairs Laws.
Of the 3,111 items, the number of re-assess...
Narcolepsy should be included in list of rare and intractable diseases, lawmaker says
Rep. Shin Sang-jin of the ruling Grand National Party has presented a petition to the National Assembly that narcolepsy must be included in a list of rare and intractable diseases for better treatment.
If the lawma...
7 drug makers fined for illicit rebates
The country’s corporate watchdog said on January 15 that it has imposed a combined 20.4 billion won in fines on seven pharmaceutical companies for unfair trading practices, including the provision of illegal rebates t...
Multinational firms back FTC action over undue rebates
The Korean Research-based Pharmaceutical Industry Association (KRPIA) said on January 16 that it has supported the Fair Trade Commission’s action to root out illicit practices, adding this should serve as a catalyst t...
Concerns grow over re-assessment of drug economic effectiveness
The Health Insurance Review and Assessment Service plans to evaluate the economic effectiveness of 3,000-odd medicines covered by national health insurance, including leading antihypertensive agents, this year, trigge...
KFDA to set aside 50.3 billion for safety research projects
The Korea Food and Drug Administration plans to spend 50.3 billion won for promotion of 146 safety research projects related to drugs, foods, medical devices this year.
In an information session on January 15, a KF...
Hanmi sales increased 10% in 2008
Hanmi Pharm’s sales increased 10 percent last year as the company saw 11 products exceed 10 billion won.
Those involved are Amordipin, antihypertensive agent (57 billion won); Medilac, preparations for intestinal f...
Ethical wholesalers in Seoul on bumpy road
Wholesalers in Seoul have been facing strong competition from its two big rivals – Zeullig Korea and RMS Korea - in the domestic drug logistics segments.
By riding on the margin-cut woes, these foreign giants are t...
